Literature DB >> 25462199

Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.

Giorgio Bogani1, William A Cliby2, Giovanni D Aletti3.   

Abstract

OBJECTIVE: To review the current evidence on the effects of intra-abdominal morcellation on survival outcomes of patients affected by unexpected uterine leiomyosarcoma (ULMS) and to estimate the risk of recurrence in those patients.
METHODS: PubMed (MEDLINE), Scopus, Embase, Web of Science databases as well as ClinicalTrials.gov, were searched for data evaluating the effects of intra-abdominal morcellation on survival outcomes of patients with undiagnosed ULMS. Studies were evaluated per the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and the American College of Obstetricians and Gynecologists (ACOG) guidelines.
RESULTS: Sixty manuscripts were screened, 11 (18%) were selected and four (7%) were included. Overall, 202 patients were included: 75 (37%) patients had morcellation of ULMS, while 127 (63%) patients had not. A meta-analysis of these studies showed that morcellation increased the overall (62% vs. 39%; OR: 3.16 (95% CI: 1.38, 7.26)) and intra-abdominal (39% vs. 9%; OR: 4.11 (95% CI: 1.92, 8.81)) recurrence rates as well as death rate (48% vs. 29%; OR: 2.42 (95% CI: 1.19, 4.92)). No between-group difference in cumulative extra-abdominal recurrence (OR: 0.34 (95% CI: 0.07, 1.59)) rate was observed.
CONCLUSIONS: Our data support a significant correlation between uterine morcellation and an increased risk of intra-abdominal recurrence in patients affected by unexpected ULMS. However, the limited data on this issue and the absence of high level of evidence suggest the need of further studies designed to estimate the risk to benefit ratio of morcellation in patients with uterine fibroids and undiagnosed ULMS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leiomyosarcoma; Morcellation; Power morcellator; Recurrence; Uterine sarcoma

Mesh:

Year:  2014        PMID: 25462199     DOI: 10.1016/j.ygyno.2014.11.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Comparison of Surgical Outcomes according to Suturing Methods in Single Port Access Laparoscopic Myomectomy.

Authors:  Jae-Heok Jeong; Yu-Ri Kim; Eun-Jeong Kim; Soo-Hyeon Moon; Mi-Hwa Park; Jeong-Tae Kim; Jeong-Hye Kim; Kyu-Sup Lee
Journal:  J Menopausal Med       Date:  2015-04-27

2.  Is Laparoscopic Power Morcellation of Fibroids a Cardinal Sin in 2017?

Authors:  Gautam N Allahbadia
Journal:  J Obstet Gynaecol India       Date:  2017-01-30

3.  Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center.

Authors:  Ann Peters; Amanda M Sadecky; Daniel G Winger; Richard S Guido; Ted T M Lee; Suketu M Mansuria; Nicole M Donnellan
Journal:  Int J Gynecol Cancer       Date:  2017-07       Impact factor: 3.437

Review 4.  Ultrasound-Guided Trans-Uterine Cavity Core Needle Biopsy of Uterine Myometrial Tumors to Differentiate Sarcoma from a Benign Lesion-Description of the Method and Review of the Literature.

Authors:  Maciej Stukan; Piotr Rutkowski; Jeremy Smadja; Sylvie Bonvalot
Journal:  Diagnostics (Basel)       Date:  2022-05-29

Review 5.  Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: A Systematic Review of the Literature.

Authors:  Jacopo Di Giuseppe; Camilla Grelloni; Lucia Giuliani; Giovanni Delli Carpini; Luca Giannella; Andrea Ciavattini
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

Review 6.  Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions.

Authors:  Klaudia Żak; Bartłomiej Zaremba; Alicja Rajtak; Jan Kotarski; Frédéric Amant; Marcin Bobiński
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

Review 7.  Medical Device Safety and Surgical Dissemination of Unrecognized Uterine Malignancy: Morcellation in Minimally Invasive Gynecologic Surgery.

Authors:  Tracilyn Hall; Susanna I Lee; David M Boruta; Annekathryn Goodman
Journal:  Oncologist       Date:  2015-09-17

8.  Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.

Authors:  Francesco Multinu; Jvan Casarin; Lucia Tortorella; Yajue Huang; Amy Weaver; Stefano Angioni; Gian Benedetto Melis; Andrea Mariani; Elizabeth A Stewart; Shannon K Laughlin-Tommaso
Journal:  Am J Obstet Gynecol       Date:  2018-11-14       Impact factor: 8.661

9.  Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.

Authors:  Francesco Multinu; Jvan Casarin; Kristine T Hanson; Stefano Angioni; Andrea Mariani; Elizabeth B Habermann; Shannon K Laughlin-Tommaso
Journal:  JAMA Surg       Date:  2018-06-20       Impact factor: 14.766

10.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.